摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4R)-4-(phenylmethoxymethyl)-1,3,2-dioxathiolane 2,2-dioxide | 185838-02-2

中文名称
——
中文别名
——
英文名称
(4R)-4-(phenylmethoxymethyl)-1,3,2-dioxathiolane 2,2-dioxide
英文别名
——
(4R)-4-(phenylmethoxymethyl)-1,3,2-dioxathiolane 2,2-dioxide化学式
CAS
185838-02-2
化学式
C10H12O5S
mdl
——
分子量
244.268
InChiKey
HGNFAVXSHSUMLA-SNVBAGLBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    370.6±11.0 °C(Predicted)
  • 密度:
    1.342±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    70.2
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT
    申请人:Chugai Seiyaku Kabushiki Kaisha
    公开号:US20190225604A1
    公开(公告)日:2019-07-25
    The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.
    本发明提供一种化合物,其具有通过取代基连接的式(I)所示的基本结构,其中吲哚环和吡唑吡啶结构通过取代基相连,以及包含该化合物、盐或该化合物的盐的溶剂的预防剂或治疗剂,用作非胰岛素依赖型糖尿病(2型糖尿病)或肥胖症的活性成分。
  • Large Scale Syntheses of N-Protected 2,3-Methanomethionine Stereoisomers
    作者:Kevin Burgess、Chun-Yen Ke
    DOI:10.1055/s-1996-4425
    日期:1996.12
    Three stereoisomers of N-protected forms of 2,3-methanomethionine (cyclopropyl derivatives of methionine, or ”cyclo-Met”) were prepared. Two of the syntheses developed involved diol (S)-1, which was more easily obtained from L-gulono-1,4-lactone than via juxtaposition of the benzyl protection of (R)-1. The cis-cyclo-Met derivative (cis refers to the orientation of the side chain relative to the amino functionality), FMOC-(2R,3S)-cyclo-Met, was obtained via a route based on a previous synthesis of (2R,3S)-cyclo-Met from the lactone 3, but the protected trans-cyclo-Met, BOC-(2R,3S)-cyclo-Met, was obtained via an improved procedure that does not involve lactone 3.
    我们制备了三种 2,3-甲硫氨酸 N 保护形式的立体异构体(甲硫氨酸的环丙基衍生物,或称 "环甲硫氨酸")。其中两种合成涉及二元醇 (S)-1,它更容易从 L-古洛萘-1,4-内酯中获得,而不是通过并置苄基保护的 (R)-1。顺式环-Met 衍生物(顺式指侧链相对于氨基官能团的取向)FMOC-(2R,3S)-环-Met 是通过以前从内酯 3 合成 (2R,3S)-cyclo-Met 的路线获得的,但受保护的反式环-Met BOC-(2R,3S)-cyclo-Met 则是通过一种不涉及内酯 3 的改进程序获得的。
  • Oxidation of organic cyclic sulfites to sulfates: a new reaction catalyzed by cyclohexanone monooxygenase
    作者:Stefano Colonna、Nicoletta Gaggero、Stefano Colonna、Giacomo Carrea、Piero Pasta
    DOI:10.1039/a707749a
    日期:——
    Cyclohexanone monooxygenase from Acinetobacter catalyzes the enantioselective oxidation of organic cyclic sulfites to sulfates.
    来自不动杆菌的环己酮单加氧酶催化有机环状亚硫酸盐到硫酸盐的对映选择性氧化。
  • Pyrazolopyridine derivative having GLP-1 receptor agonist effect
    申请人:Chugai Seiyaku Kabushiki Kaisha
    公开号:US10858356B2
    公开(公告)日:2020-12-08
    The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.
    本发明提供了一种具有式(I)所示基本结构(其中吲哚环和吡唑并吡啶结构通过取代基结合)的化合物、其盐或该化合物或该化合物盐的溶液,以及以该化合物、盐或溶液为有效成分的非胰岛素依赖型糖尿病(2 型糖尿病)或肥胖症的预防剂或治疗剂。
  • SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
    申请人:JAPAN TOBACCO INC.
    公开号:US20170044156A1
    公开(公告)日:2017-02-16
    Provided is a substituted spiropyrido[1,2-a]pyrazine derivative or a pharmaceutically acceptable salt thereof, which is useful as an anti-HIV agent. The present invention relates to a compound represented by the following formula [I] or [II] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the specification.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐